NCT02670031 Response of the Myocardium to Hypertrophic Conditions in the Adult Population
| NCT ID | NCT02670031 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Heart Centre Singapore |
| Condition | Left Ventricular Hypertrophy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2016-01 |
| Primary Completion | 2031-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2016-01 with a primary completion date of 2031-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function. Ultimately, heart failure occurs as a result of progressive muscle cell death and scarring (myocardial fibrosis). Dedicated techniques using cardiovascular magnetic resonance imaging (MRI) and novel high-sensitivity cardiac troponin blood assays are potential markers to detect myocardial fibrosis. Although hypertension-related heart disease is very common in Singapore, the significance of myocardial fibrosis is not well understood. In this study, the significance of myocardial fibrosis in 2000 patients with hypertension would be investigated. This will be the largest study using state-of-the-art MRI to examine the importance of myocardial fibrosis in hypertensive heart disease. 1000 participants, with at least 1 year follow-up, will be invited for a repeat assessment.
Eligibility Criteria
Inclusion Criteria: 1. 21 years and over 2. Physician diagnosed essential hypertension, on at least 1 medication for blood pressure control 3. Newly diagnosed hypertension: systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) on at least 2 office visits (Weber 2013) and not started on any anti hypertensive medications at time of ambulatory blood pressure monitoring 4. Resistant hypertension: persistent systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) despite on at least 3 anti-hypertensive medications (Jennings 2013; Weber 2013) Exclusion Criteria: 1. Known secondary hypertension: renal causes (renal artery stenosis, chronic renal failure); endocrine causes (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism); cardiac causes (coarctation of the aorta) 2. Contraindications to cardiovascular magnetic resonance: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF \<30ml/min/1.73m2), claustrophobia and women who are pregnant or breast-feeding 3. Limited life expectancy 4. On-going unstable medical conditions: hypertensive crisis, acute coronary syndromes or acute heart failure 5. History of coronary artery disease, ischemic heart disease 6. History of transient ischemic attacks or cerebrovascular events 7. History of atrial fibrillation 8. History of heart failure
Contact & Investigator
Calvin WL Chin, MBBS, PhD
PRINCIPAL INVESTIGATOR
National Heart Centre Singapore
Frequently Asked Questions
Who can join the NCT02670031 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 99 Years, studying Left Ventricular Hypertrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02670031 currently recruiting?
Yes, NCT02670031 is actively recruiting participants. Contact the research team at liew.mu.jie@nhcs.com.sg for enrollment information.
Where is the NCT02670031 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT02670031 clinical trial?
NCT02670031 is sponsored by National Heart Centre Singapore. The principal investigator is Calvin WL Chin, MBBS, PhD at National Heart Centre Singapore. The trial plans to enroll 2,000 participants.